Biotechs need to get used to the new normal, says SR One CEO and Managing Partner Simeon George, and that will require significant adjustments to the business model. This new normal comes from an extended tough capital environment against a backdrop of political uncertainty, but while biotechs face a different set of factors than they have in the past, there are still first principles of value creation that should guide them.
George, who co-founded SR One management in 2020 following its spinout from GSK, spoke on The BioCentury Show with Editor in Chief Simone Fishburn about the challenges facing biotechs and how VCs are navigating through the complexity of the moment. He also discussed SR One’s strategy and philosophy of investing.
View full story: https://www.biocentury.com/article/655142
00:00 - Introduction
01:31 - Meeting the Moment
04:45 - Company Valuations
13:54 - China Strategy, NewCos
22:08 - Building Successful Biotechs
#biotech #biopharma #pharma #lifescience #CEO #financing #newco